|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US20230050345A1
(en)
*
|
2013-05-13 |
2023-02-16 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotheraphy
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
US10357515B2
(en)
*
|
2013-11-22 |
2019-07-23 |
Cellectis |
Method for generating batches of allogeneic T-cells with averaged potency
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
CA2943008C
(en)
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
WO2016124765A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
|
KR20260048600A
(ko)
*
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
EP3283520B1
(en)
|
2015-04-13 |
2020-05-06 |
Pfizer Inc |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
JP6949728B2
(ja)
*
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
|
|
EP4043556B1
(en)
*
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
AU2016369490C1
(en)
*
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
EA201891641A1
(ru)
|
2016-01-21 |
2019-01-31 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
|
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039333A1
(en)
*
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
KR102622910B1
(ko)
|
2016-09-08 |
2024-01-10 |
2세븐티 바이오, 인코포레이티드 |
Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
|
MA46236A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
|
JP2020500031A
(ja)
*
|
2016-10-11 |
2020-01-09 |
ミネルバ バイオテクノロジーズ コーポレーション |
ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
AU2018221730B2
(en)
|
2017-02-15 |
2024-06-20 |
Novo Nordisk A/S |
Donor repair templates multiplex genome editing
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
JP7317718B2
(ja)
|
2017-06-02 |
2023-07-31 |
ファイザー・インク |
Ｆｌｔ３を標的にするキメラ抗原受容体
|
|
CA3068286A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
SG10201705285SA
(en)
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
US12144825B2
(en)
|
2017-06-30 |
2024-11-19 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019018402A2
(en)
|
2017-07-17 |
2019-01-24 |
Janssen Biotech, Inc. |
ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
|
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
|
US11903968B2
(en)
|
2017-07-21 |
2024-02-20 |
Cellectis |
Engineered immune cells resistant to tumor microenvironment
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
MX2020005495A
(es)
*
|
2017-10-20 |
2021-01-08 |
Pharmabcine Inc |
Anticuerpo anti-vista y uso del mismo.
|
|
JP7261232B2
(ja)
|
2017-11-01 |
2023-04-19 |
アロジーン セラピューティクス，インコーポレイテッド |
改変カスパーゼ－９ポリペプチドおよびその使用方法
|
|
JP2021502077A
(ja)
*
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US20210002621A1
(en)
*
|
2017-12-20 |
2021-01-07 |
Bluebird Bio, Inc. |
Ctla4 homing endonuclease variants, compositions, and methods of use
|
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
KR102780406B1
(ko)
|
2018-02-01 |
2025-03-17 |
화이자 인코포레이티드 |
Cd70을 표적으로 하는 키메라 항원 수용체
|
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Ｉｌ−１５バリアントおよびその使用
|
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
WO2020007593A1
(en)
|
2018-07-02 |
2020-01-09 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
SG11202101773WA
(en)
|
2018-08-29 |
2021-03-30 |
Nanjing Legend Biotech Co Ltd |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
WO2020055962A1
(en)
*
|
2018-09-11 |
2020-03-19 |
Board Of Regents, The University Of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US20200268797A1
(en)
|
2018-11-30 |
2020-08-27 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
|
US12577547B2
(en)
|
2018-12-10 |
2026-03-17 |
Regeneron Pharmaceuticals, Inc. |
PDCD-1 homing endonuclease variants
|
|
WO2020123371A2
(en)
|
2018-12-10 |
2020-06-18 |
Bluebird Bio, Inc. |
Homing endonuclease variants
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
MX2021009357A
(es)
*
|
2019-02-04 |
2021-11-17 |
Ksq Therapeutics Inc |
Dianas de genes de combinacion para mejorar la inmunoterapia.
|
|
EP3693974A1
(en)
*
|
2019-02-07 |
2020-08-12 |
Koninklijke Philips N.V. |
Identifying responsiveness to radio-immuno combination therapy
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
JP2022546364A
(ja)
|
2019-08-27 |
2022-11-04 |
ヤンセン バイオテツク，インコーポレーテツド |
キメラ抗原受容体系及びその使用
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
JP2022554217A
(ja)
*
|
2019-10-23 |
2022-12-28 |
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ |
養子免疫療法
|
|
WO2021176373A1
(en)
|
2020-03-03 |
2021-09-10 |
Janssen Biotech, Inc. |
ꝩδ T CELLS AND USES THEREOF
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
EP4185610A2
(en)
|
2020-07-21 |
2023-05-31 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
AU2022224066A1
(en)
*
|
2021-02-19 |
2023-09-07 |
Angeles Therapeutics, Inc. |
Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
|
|
BR112023018948A2
(pt)
*
|
2021-03-19 |
2023-10-17 |
Metagenomi Inc |
Edição multiplex com enzimas cas
|
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
CN118891374A
(zh)
|
2022-03-24 |
2024-11-01 |
南京传奇生物科技有限公司 |
制备dna文库和检测逆转录病毒整合位点的方法
|
|
US20260035424A1
(en)
|
2022-05-26 |
2026-02-05 |
Caribou Biosciences, Inc. |
Cytokine-receptor fusions for immune cell stimulation
|
|
AU2023285071B2
(en)
|
2022-06-06 |
2025-02-20 |
Caribou Biosciences, Inc. |
Treatment of autoimmune diseases with engineered immune cells
|
|
EP4583890A1
(en)
|
2022-09-09 |
2025-07-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
EP4583889A1
(en)
|
2022-09-09 |
2025-07-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
WO2024088401A1
(en)
*
|
2022-10-28 |
2024-05-02 |
CorrectSequence Therapeutics Co., Ltd |
Gene editing systems and methods for reducing immunogenicity and graft versus host response
|
|
EP4584283A1
(en)
|
2022-11-14 |
2025-07-16 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|
|
KR20240076377A
(ko)
|
2022-11-23 |
2024-05-30 |
가톨릭대학교 산학협력단 |
인간 혈청 알부민을 이용한 면역억제 t 세포의 대량 생산 방법
|
|
AU2024265453A1
(en)
|
2023-05-01 |
2025-09-25 |
Caribou Biosciences, Inc. |
Treatment of autoimmune diseases with bcma-targeting engineered immune cells
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025193386A1
(en)
|
2024-03-13 |
2025-09-18 |
Caribou Biosciences, Inc. |
Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
|